REDUCING PRESCRIPTION DRUG COSTS FOR AMERICANS: Today, President Donald J. Trump unveiled nine strategic agreements with prominent pharmaceutical companies aimed at slashing prescription drug prices for Americans to align with the lowest rates seen in other developed nations, a concept often referred to as the most-favored-nation (MFN) pricing.
- The nine participating manufacturers are Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi.
- These agreements will significantly lower prices for medications addressing a range of expensive and chronic health issues, including type two diabetes, rheumatoid arthritis, multiple sclerosis, asthma, chronic obstructive pulmonary disease (COPD), hepatitis B and C, human immunodeficiency virus (HIV), and various cancers, among others.
- Every State Medicaid program will gain access to MFN drug prices from these nine companies, leading to billions in savings and reinforcing President Trump’s commitment to fortifying the program for the nation’s most vulnerable populations.
- These agreements also prevent foreign countries from exploiting American innovation by ensuring MFN pricing applies to all new, innovative products launched by the companies involved.
- Additionally, the agreements mandate that these firms bring back additional foreign revenues from existing products, a move designed to benefit American patients through the President’s robust America First trade policies.
- Finally, the agreements stipulate that these companies must provide substantial discounts on their products when sold directly to American patients through TrumpRx.
BRINGING DOWN COSTS FOR PATIENTS: As a direct result of these agreements, patients can expect dramatic price reductions on a variety of medications when purchasing through TrumpRx. Here are a few notable examples:
- Amgen will reduce the price of its cholesterol-lowering drug Repatha from $573 to $239 for patients buying directly through TrumpRx.
- Bristol Myers Squibb will lower the price of its HIV medication, Reyataz, from $1,449 to $217 for direct purchases via TrumpRx.
- Boehringer Ingelheim will decrease the price of Jentadeuto, a type two diabetes medication, from $525 to $55 for patients using TrumpRx.
- Genentech will cut the price of its flu treatment, Xofluza, from $168 to $50 for those purchasing through TrumpRx.
- Gilead Sciences will drop the cost of its Hepatitis C medication, Epclusa, from $24,920 to $2,425 for direct procurement via TrumpRx.
- GSK will reduce costs for its inhaler portfolio, with the asthma inhaler Advair Diskus 500/50 seeing a price cut from $265 to $89 through TrumpRx.
- Merck’s diabetes medication, Januvia, will be available for $100 instead of $330 when purchased through TrumpRx.
- Novartis will slash the cost of its Multiple Sclerosis treatment, Mayzent, from $9,987 to $1,137 for direct purchases via TrumpRx.
- Sanofi will decrease the price of its prescription blood thinner, Plavix, from $756 to $16 for TrumpRx customers, and will also offer its insulin products at a monthly rate of $35.
STRENGTHENING NATIONAL HEALTH SECURITY THROUGH INVESTMENT: The pharmaceutical companies involved in these agreements are collectively committing to invest at least $150 billion in U.S. manufacturing in the near future. Furthermore, several firms will be donating active pharmaceutical ingredients for essential products to the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR). This initiative aims to bolster U.S. self-sufficiency and ensure a steady supply of critical medications during emergencies.
- GSK will provide 98.8 kg of albuterol, a key ingredient in common rescue inhalers for asthma patients.
- Bristol Myers Squibb will contribute tablets equivalent to 6.5 tons of apixaban, the active component in Eliquis, a widely used blood thinner.
- Merck is set to donate 3.5 tons of ertapenem, an antibacterial used for complex infections.
FULFILLING COMMITMENTS TO PRIORITIZE AMERICAN PATIENTS: President Trump is making good on his promise to ensure that American patients no longer bear the burden of exorbitant prices that effectively subsidize lower prices in other countries—a feat many in the political establishment deemed impossible.
- On May 12, 2025, President Trump signed an Executive Order titled “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients,” which set the stage for various actions aimed at aligning American drug prices with those in similar nations.
- On July 31, 2025, he addressed leading pharmaceutical manufacturers, outlining the necessary steps they must take to bring U.S. prescription drug prices in line with the lowest rates in developed nations.
- Since September 30, 2025, President Trump has announced 14 agreements with major pharmaceutical companies aimed at aligning prices with those paid in other developed countries, offering substantial relief on numerous medications essential to millions of Americans.
- On December 1, 2025, the Office of the United States Trade Representative, alongside the Department of Commerce and the Department of Health and Human Services, reached an agreement with the United Kingdom to increase the net price of new prescription drugs by 25% in the U.K., ensuring they contribute their fair share for innovative treatments.
